Scientific Writing in Pharmacovigilance

Scientific writing in pharmacovigilance is the disciplined communication of evidence, uncertainty and judgement for readers who may need to make regulatory or clinical decisions. The objective is not persuasive prose. It is to make the evidence base, reasoning and limits of the conclusion sufficiently clear that another qualified reviewer can follow—and if necessary challenge—the argument.

Purpose and Regulatory Context

Different pharmacovigilance documents have different formal requirements. ICH E2C(R2) defines the PBRER structure, ICH E2F defines the DSUR, GVP Module V governs the RMP framework and GVP Module IX governs signal management. None of these replaces scientific judgement.

Across document types, good writing performs the same underlying function:

evidence → observation → interpretation → conclusion → regulatory consequence.

The exact wording and level of detail vary by document, but each step should remain traceable to the one before it.

Scientific Writing Is Part of Scientific Reasoning

Writing is not merely the final stage after an assessment has been completed. Attempting to explain a conclusion often exposes gaps in the assessment itself.

If the author cannot explain why one study was weighted more heavily than another, why confounding was considered important, or why contradictory evidence did not alter the conclusion, the problem is not stylistic. The reasoning requires further work.

This is why experienced pharmacovigilance authors often draft and analyse iteratively. Writing becomes a test of whether the scientific argument is coherent.

Start With Evidence, Not the Desired Conclusion

The most important discipline is to separate what the evidence shows from what the organisation might prefer the conclusion to be.

Relevant evidence can include:

• ICSRs and case series;
• clinical-trial data;
• epidemiological studies;
• PASS and other post-authorisation studies;
• scientific literature;
• non-clinical or mechanistic evidence;
• product utilisation data; and
• regulatory assessments.

Evidence sources differ in what they can establish. A spontaneous-reporting pattern may generate or strengthen a hypothesis but usually cannot estimate incidence reliably. A randomised trial may support causal inference but be underpowered for rare outcomes. An observational study may quantify risk but remain vulnerable to confounding.

Scientific writing should make those strengths and limitations visible rather than flattening all sources into a single narrative.

Observation, Interpretation and Action

One of the most useful writing distinctions is between three levels.

Observation

A statement of what was found: for example, a number of cases, an incidence estimate, a study result or a reporting pattern.

Interpretation

The scientific meaning assigned to those observations after considering quality, bias, confounding, plausibility and competing explanations.

Action

The regulatory or risk-management consequence, such as further evaluation, product-information change, RMP update or additional risk minimisation.

These levels should not be collapsed. A regulatory action is not itself proof of causality, and a numerical observation is not automatically a scientific conclusion.

Communicating Uncertainty

Uncertainty is intrinsic to pharmacovigilance. The quality of writing is therefore partly determined by whether the language expresses the strength of evidence rather than the author's confidence.

Terms such as caused, confirmed, established or no evidence of risk should be used only when the underlying evidence supports that level of certainty. Conversely, excessive hedging can obscure a robust conclusion.

Useful writing distinguishes:

• what is known with reasonable confidence;
• what is plausible but unconfirmed;
• what evidence is conflicting;
• what information is missing; and
• what further evidence could resolve the uncertainty.

This is especially important in signal assessments and benefit-risk evaluations, where the decision may need to proceed despite incomplete evidence.

Present Contradictory Evidence Fairly

Selective citation weakens regulatory credibility. If a well-conducted epidemiological study does not support an association suggested by spontaneous reports, both should be discussed. If a clinical-trial imbalance exists but the number of events is very small, that limitation should be explicit.

Balanced writing does not require giving every source equal weight. It requires explaining why some evidence is more informative than other evidence.

A useful structure is:

1. present the relevant evidence;
2. identify the methodological strengths and limitations;
3. explain whether sources converge or conflict; and
4. state how the totality of evidence supports the conclusion.

Proportionality

The depth of discussion should reflect the importance and uncertainty of the scientific question, not the amount of available text.

A major new safety signal with potential benefit-risk consequences may require substantial discussion. A stable known risk with no meaningful new evidence may require only a concise update.

Proportionality prevents two common problems: burying important conclusions in excessive detail and giving trivial observations disproportionate prominence.

Precision of Terminology

Regulatory terms have specific meanings. Authors should distinguish, for example:

• adverse event from adverse reaction;
• signal from validated signal or confirmed risk;
• identified risk from potential risk;
• seriousness from severity;
• association from causation; and
• missing information from ordinary lack of data.

Terminological inconsistency can become a scientific inconsistency. If one section calls an issue a “confirmed risk” while another describes causality as uncertain, the reader cannot know which interpretation represents the organisation's position.

Quantitative Writing

Numbers should clarify rather than decorate an argument.

Where numerical claims are material, the reader should be able to understand the denominator, time period and analytical context. “Twenty cases were reported” has different meaning in 2,000 exposed patients than in 2 million, and spontaneous-reporting counts cannot generally be converted into incidence without a valid denominator.

Similarly, relative measures should be accompanied by enough context to judge absolute importance where feasible. Confidence intervals and uncertainty should be reported when they materially affect interpretation.

Causality Language

Pharmacovigilance documents frequently discuss causal relationships under uncertainty. Writing should reflect the evidential stage.

Statements such as “the cases demonstrate that the product causes…” are inappropriate when the evidence only supports a possible association. More accurate wording may describe the evidence as supporting, strengthening, weakening or not establishing a causal association.

Causality assessment is not made stronger by stronger adjectives. It is made stronger by better evidence and clearer reasoning.

Internal Consistency Across Documents

A medicinal product's scientific narrative is distributed across multiple records: signal assessments, RMPs, PSUR/PBRERs, study reports, regulatory responses and product information.

These documents need not use identical wording, but material conclusions should be reconcilable. If a signal assessment concludes that an association is unsupported while the next PBRER describes the same issue as an emerging confirmed risk, the change in interpretation must be explained.

Cross-document consistency is therefore part of pharmacovigilance governance, not merely editing.

Writing for Different Pharmacovigilance Documents

The scientific principles are stable, but document purpose changes emphasis.

A good author therefore starts by asking what decision the reader needs to make and what evidence is necessary for that decision.

Review and Quality Control

Scientific review should test reasoning, not only grammar. A useful review asks:

• Are important conclusions supported by identifiable evidence?
• Is contradictory evidence represented fairly?
• Are uncertainty and limitations explicit?
• Are association and causation distinguished?
• Do numbers have appropriate denominators and context?
• Does the conclusion follow from the evidence presented?
• Are proposed actions consequences of the conclusion rather than substitutes for it?
• Is terminology consistent across the document and related safety records?

Editorial review should then improve structure, clarity, concision and consistency without changing scientific meaning inadvertently.

Potential Failure Modes

The following are illustrative writing failures, not published inspection findings.

Practical Writing Checklist

The following checklist is recommended professional practice, not a regulatory template.

1. What decision or scientific question is this section intended to support?
2. What are the strongest relevant sources of evidence?
3. Have observation and interpretation been separated?
4. Have important contradictory findings been addressed?
5. Does the language match the strength of evidence?
6. Are quantitative statements interpretable and correctly contextualised?
7. Are limitations material to the conclusion stated explicitly?
8. Does each major conclusion follow logically from the preceding evidence?
9. Are regulatory recommendations clearly distinguished from scientific findings?
10. Is terminology consistent with related RMP, PBRER, signal and product-information records?
11. Can a reviewer trace the conclusion back to evidence?
12. Can unnecessary text be removed without losing reasoning?

Key Takeaways

Scientific writing in pharmacovigilance is scientific reasoning made visible.

The central discipline is to maintain the chain evidence → observation → interpretation → conclusion → action without allowing one stage to substitute for another.

Good writing communicates uncertainty honestly, presents conflicting evidence fairly, uses precise regulatory terminology and gives detail in proportion to the scientific importance of the issue.

The strongest document is not the longest or most confident. It is the one in which a qualified reader can understand what is known, what remains uncertain, why the conclusion was reached and what evidence supports the resulting action.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER).
2. International Council for Harmonisation. ICH E2F: Development Safety Update Report (DSUR).
3. International Council for Harmonisation. ICH E2E: Pharmacovigilance Planning.
4. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V — Risk management systems (Rev. 2).
5. European Medicines Agency. GVP Module VII — Periodic safety update report (Rev. 1).
6. European Medicines Agency. GVP Module IX — Signal management (Rev. 1).
7. European Medicines Agency. GVP Module I — Pharmacovigilance systems and their quality systems.
8. European Union. Commission Implementing Regulation (EU) No 520/2012, consolidated version current at 12 February 2026.

Regulatory Note

Scientific-writing principles are not a separate EU legal code. Binding content and procedural requirements arise from the legislation and guidance applicable to the document being prepared. This article presents a professional method for communicating evidence and reasoning consistently across those regulated documents.